Brighton Biotech Inc. (BBI) is focused on developing pharmaceutical and biotechnology products aimed at addressing serious unmet medical needs. The company employs a unique strategy by partnering with leading academic institutions and leveraging a global network of drug development resources. This approach allows BBI to expedite the development process of its products while minimizing costs, effectively providing the capabilities of a large pharmaceutical company without the need for a traditional infrastructure.

One of the key products in BBI's pipeline is N-Acetylcysteine Amide (NACA), recognized as a potent small molecule antioxidant. NACA is being explored for its potential to mitigate the harmful effects of oxidation, particularly in the context of Chronic Traumatic Encephalopathy (CTE) and Neurocognitive Disorders (NCD). BBI is committed to pursuing these therapeutic indications, which represent significant opportunities for accelerated development in the pharmaceutical landscape.

United States

BBI, headquartered in New York, is a privately held company founded in 2010 that specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and/or prevention of serious unmet medical needs.

The COMPANY’s focus is to develop its products as quickly and as efficiently as possible, saving time and resources. We have partnered with leading academic institutions as well as a global network of drug development resources, eliminating the need and cost to build a "brick and mortar" biotech company. This innovative approach gives BBI big pharma capabilities without a big pharma infrastructure.

Brighton Biotech

Company Details